Treatment of hereditary angioedema in the pediatric patient

Shana Kalaria, Timothy Craig

Research output: Contribution to journalArticle

Abstract

Hereditary angioedema (HAE) is an autosomal dominant disease, with the expectation that there is a risk of 50%, if a parent has HAE, of inheriting the disease. Manifestations of the disease start early in life for some patients, but symptoms frequently increase during the transition from childhood to adolescence. Unfortunately, most medications are not approved for use in children. This requires off-label use for most of the medications that are U.S. Food and Drug Administration approved for HAE. For this reason, we have sought to identify the use of medications approved and unapproved and used off label for children with HAE.

Original languageEnglish (US)
Pages (from-to)171-175
Number of pages5
JournalPediatric, Allergy, Immunology, and Pulmonology
Volume27
Issue number4
DOIs
StatePublished - Dec 1 2014
Externally publishedYes

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Treatment of hereditary angioedema in the pediatric patient'. Together they form a unique fingerprint.

  • Cite this